NKGN: Utang jangka cendhak perusahaan NKGen Biotech

This chart of NKGen Biotech, Inc. (NKGN) asset value demonstrates the dynamics of a company developing advanced treatments for dementia and oncology through immune cell modification. The current figure is 0.00. The business faces clinical trial uncertainty and a funding shortage, while operational processes are strictly limited by FDA medical standards regarding biological waste processing.

This metric measures total liabilities with a maturity of up to one year, allowing for the rapid identification of liquidity risks and phases of accumulating credit pressure. By analyzing the level of short-term obligations, an investor assesses the financial stability of NKGen Biotech, Inc. (NKGN), which is critical for sustaining costly research and development in the field of Alzheimer's and Parkinson's disease therapies using NK cells.